Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized human immunodeficiency virus type 1 pol gene

被引:37
作者
Casimiro, DR
Tang, AM
Perry, HC
Long, RS
Chen, MC
Heidecker, GJ
Davies, ME
Freed, DC
Persaud, NV
Dubey, S
Smith, JG
Havlir, D
Richman, D
Chastain, MA
Simon, AJ
Fu, TM
Emini, EA
Shiver, JW
机构
[1] Merck & Co Inc, Merck Res Labs, Dept Virus & Cell Biol, W Point, PA 19486 USA
[2] Univ Calif San Diego, La Jolla, CA 92103 USA
[3] VA San Diego Healthcare Syst, La Jolla, CA 92103 USA
关键词
D O I
10.1128/JVI.76.1.185-194.2002
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
A synthetic gene consisting of the reverse transcriptase (RT) and integrase (IN) domains of human immunodeficiency virus type 1 (HIV-1) pol was constructed using codons most frequently used in humans. The humanized pol gave dramatically improved levels of Rev-independent, in vitro protein production in mammalian cells and elicited much stronger cellular immunity in rodents than did virus-derived gene. Specifically, BALB/c mice were immunized with plasmids and/or recombinant vaccinia virus constructs expressing the synthetic gene. High frequencies of Pot-specific T lymphocytes were detected in these animals by the gamma interferon enzyme-linked immunospot assay against pools of short overlapping peptides. Characterization of the stimulatory peptides from these pools indicates that the optimized gene constructs are able to effectively activate both CD4(+) and CD8(+) T cells. Immunization of rhesus macaques with DNA vaccines expressing the humanized pol coupled to a human tissue plasminogen activator leader sequence led to pronounced in vitro cytotoxic T-lymphocyte killing activities and enhanced levels of circulating Pol-specific T cells, comparable to those observed in HIV-1-infected human subjects. Thus, optimizing the immunogenic properties of HIV-1 Pot at the level of the gene sequence validates it as an antigen and provides an important step toward the construction of a potent pol-based HIV-1 vaccine component.
引用
收藏
页码:185 / 194
页数:10
相关论文
共 46 条
[41]   Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes [J].
Schmitz, JE ;
Kuroda, MJ ;
Santra, S ;
Sasseville, VG ;
Simon, MA ;
Lifton, MA ;
Racz, P ;
Tenner-Racz, K ;
Dalesandro, M ;
Scallon, BJ ;
Ghrayeb, J ;
Forman, MA ;
Montefiori, DC ;
Rieber, EP ;
Letvin, NL ;
Reimann, KA .
SCIENCE, 1999, 283 (5403) :857-860
[42]   Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge [J].
Seth, A ;
Ourmanov, I ;
Schmitz, JE ;
Kuroda, MJ ;
Lifton, MA ;
Nickerson, CE ;
Wyatt, L ;
Carroll, M ;
Moss, B ;
Venzon, D ;
Letvin, NL ;
Hirsch, VM .
JOURNAL OF VIROLOGY, 2000, 74 (06) :2502-2509
[43]   Humoral and cellular immunities elicited by HIV-1 DNA vaccination [J].
Shiver, JW ;
Davies, ME ;
Perry, HC ;
Freed, DC ;
Liu, MA .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1996, 85 (12) :1317-1324
[44]  
SHIVER JW, VACCINES 95, P95
[45]   Protection by live, attenuated simian immunodeficiency virus against heterologous challenge [J].
Wyand, MS ;
Manson, K ;
Montefiori, DC ;
Lifson, JD ;
Johnson, RP ;
Desrosiers, RC .
JOURNAL OF VIROLOGY, 1999, 73 (10) :8356-8363
[46]   A ''humanized'' green fluorescent protein cDNA adapted for high-level expression in mammalian cells [J].
Zolotukhin, S ;
Potter, M ;
Hauswirth, WW ;
Guy, J ;
Muzyczka, N .
JOURNAL OF VIROLOGY, 1996, 70 (07) :4646-4654